A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has spread across the world, prompting the World Health Organization to declare the …

Abstract Coronavirus disease‐2019 (COVID‐19) has emerged as a novel infection which
has spread rapidly across the globe and currently presents a grave threat to the health of …

The present review summarizes up-to-date evidence addressing the frequently discussed
clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer …

In late December 2019, a new infectious viral disease appeared. A new betacoronavirus,
severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has been recognized as …

Infectious diseases represent a relevant issue in lung cancer patients. Bacterial and viral
infections might influence the patients' prognosis, both directly affecting the immune system …

The COVID-19 pandemic has inevitably caused those involved in cancer care to change
clinical practice in order to minimize the risk of infection while maintaining cancer treatment …

Background This study was designed to investigate whether COVID-19 patients with
recently received immunotherapy or other anti-cancer treatments had more severe …

The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan,
China, in December 2019, and its global dissemination became the coronavirus disease …

Background The association between immune checkpoint inhibitor (ICI) and outcomes of
cancer patients with coronavirus disease 2019 (COVID-19) infection has yet to be …

Simple Summary The introduction of immune checkpoint inhibitors (ICI) in 2011
revolutionized the management of many solid cancers and hematological malignancies …